Choose the path to rapid* and sustained K+ control2,4

 

In a retrospective analysis of STUDY 3,

89% of patients continued RAAS inhibitor (RAASi) use‡5
 

*In Study 1, LOKELMA 10 g tid demonstrated a greater reduction in serum K+ levels vs placebo at 48 hours (P<0.001) and started to work as early as 1 hour in patients with hyperkalemia not on dialysis.2,4

In Study 2, patients with hyperkalemia who achieved normokalemia with LOKELMA in the 48-hour initial phase entered into the 28-day maintenance phase, where those who continued LOKELMA maintained lower mean serum K+ levels vs those who switched to placebo, with a greater proportion of patients having mean serum K+ in the normal range with LOKELMA vs placebo. Patients in Study 2 who continued into the open-label, 11-month extension phase sustained normokalemia with continued LOKELMA dosing.2

In a retrospective analysis of data from Study 3, 483 patients were receiving RAAS inhibitor at baseline. Of those patients, 74% maintained dose, 13% increased dose, 14% decreased dose, and 11% discontinued RAAS inhibitor use during the 12-month open-label trial. Patients were counted more than once if they required more than 1 RAAS inhibitor adjustment, so the total percentage across all 4 categories may exceed 100%.5

K+=potassium; RAAS=renin-angiotensin-aldosterone system; tid=3 times a day.